Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.25
+5.0%
$1.08
$0.60
$4.18
$53.40M0.65442,846 shs380,193 shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$7.96
-2.1%
$9.25
$4.44
$11.80
$169.86M-0.16129,219 shs116,327 shs
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$1.10
$1.09
$0.26
$1.28
$116.26M1.61957,342 shsN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$0.59
+0.4%
$0.54
$0.38
$8.98
$54.09M1.75586,163 shs136,657 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
+5.04%-3.85%+8.70%+15.74%-56.60%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-2.09%-7.87%-19.02%-8.29%+12.91%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00%0.00%0.00%0.00%0.00%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
+0.43%-10.88%-3.99%+23.20%-92.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3.0913 of 5 stars
3.53.00.00.00.65.00.6
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
2.8858 of 5 stars
3.50.00.00.02.75.00.6
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4.3428 of 5 stars
3.13.00.04.73.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3.00
Buy$8.33566.67% Upside
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3.00
Buy$17.00113.57% Upside
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00
N/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.20
Hold$8.001,262.17% Upside

Current Analyst Ratings Breakdown

Latest VRCA, NVCT, SCTL, and HOWL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/9/2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.00
4/30/2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $15.00
4/9/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/8/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
4/2/2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$17.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.88M29.83N/AN/A$1.65 per share0.76
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/A$0.50 per shareN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$94.64M1.23N/AN/A$0.56 per share1.96
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$7.57M7.18N/AN/A($0.11) per share-5.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
-$13.27M-$0.15N/AN/A-14.03%-23.82%-8.80%N/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$76.58M-$1.20N/AN/AN/AN/AN/A-145.63%8/13/2025 (Estimated)

Latest VRCA, NVCT, SCTL, and HOWL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million
5/8/2025Q1 2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A
5/6/2025Q1 2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.30-$0.27+$0.03-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
N/AN/AN/AN/AN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
0.46
8.09
8.09
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/A
3.28
3.28
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.01
1.07
0.86
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/A
1.34
1.26

Institutional Ownership

CompanyInstitutional Ownership
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
64.84%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
96.77%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
87.15%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
23.60%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
30.52%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
7.60%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
54.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
4044.87 million34.28 millionOptionable
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
820.89 million14.52 millionNot Optionable
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
258105.69 million97.66 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4092.49 million42.55 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Werewolf Therapeutics stock logo

Werewolf Therapeutics NASDAQ:HOWL

$1.25 +0.06 (+5.04%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$1.23 -0.02 (-2.00%)
As of 06/23/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Nuvectis Pharma stock logo

Nuvectis Pharma NASDAQ:NVCT

$7.96 -0.17 (-2.09%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$7.98 +0.02 (+0.25%)
As of 06/23/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Societal CDMO stock logo

Societal CDMO NASDAQ:SCTL

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$0.59 +0.00 (+0.43%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$0.58 0.00 (-0.39%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.